What drives short-term moves in ALNA stock?

Short-term moves in ALNA stock are driven by clinical updates, trial enrollment news, retail flow and sector rotation. High intraday volume and low per-share price increase volatility and execution risk for traders.

What is Meyka AI’s view on ALNA stock price potential?

Meyka AI's forecast model projects a 12-month central case of USD 0.25 for ALNA stock, implying +233.33% from USD 0.075. This is a model projection and not a guarantee.

Are there published analyst price targets for Allena Pharmaceuticals?

There are no broad sell-side consensus price targets publicly available for Allena Pharmaceuticals. Most coverage is limited, so model-based forecasts and company updates guide price expectations.

What financial metrics should investors watch for ALNA stock?

Investors should watch cash per share (USD 0.92), cash burn/free cash flow, EPS trend (currently -0.64), and any guidance on fundraising or partnerships that affect dilution and runway.

US Stocks

ALNA (Allena Pharmaceuticals) NASDAQ Pre-Market 03 Mar 2026: $0.08 heavy volume, catalysts ahead

ByHuzaifa Zahoor March 3, 2026March 3, 2026

ALNA stock is trading in the pre-market on NASDAQ at USD 0.075, up roughly 3.16% from the prior close on unusually high volume. The move follows sustained retail interest and newsflow in the biotech sector that keeps penny biotech names active. Allena Pharmaceuticals, Inc. (ALNA) remains a speculative play tied to clinical progress for lead candidate ALLN-346 and balance-sheet runway. In this pre-market most-active snapshot we break down the trading picture, financial metrics, Meyka AI grade, and a model-based forecast for investors and active traders.